IBB ETF

A major trend expected by 2025 is the growth of Biotechnology, along with a positive outlook for some biotechnology stocks.

The biotech industry is considered stable and not affected by economic changes because people always need medications and healthcare. After the pandemic, there has been a rise in mergers and acquisitions, as well as funding in this sector. Biotech is a rapidly growing field in innovation and productivity in the US, with an expected growth rate of 14% per year over the next ten years.

Join Melissa Lee from CNBC and the Fast Money traders for the last trades of the day. They will discuss the final market moves and insights. Don't miss out on their expert analysis!

I maintain a hold rating on IBB because its valuation is high at almost 20 times earnings and the technical indicators are mixed. Even though it has gained 7% this year, IBB has not performed as well as the S&P 500, which has increased by 21%, resulting in negative alpha. Important support and resistance levels to monitor are between $138-$141 and $150, with a possible upward movement to $160.

After a long period of stability and decline after the pandemic boost, the biotechnology sector is preparing for a possible breakout and a change in its story. The iShares Biotechnology ETF NASDAQ: IBB shows that the sector has made an important turnaround, with former resistance levels now acting as support, which could lead to a shift in momentum.

Exchange-traded funds (ETFs) are not only for cautious investors. A lot of these funds can provide access to some excellent growth stocks.

The iShares Biotechnology ETF (IBB) was launched on February 5, 2001, and is a smart beta exchange-traded fund that offers wide access to the Health Care ETFs sector in the market.

Here we are, another week and another gain in the bull market. Last weekend, we had a positive outlook for Small Caps, Biotechnology, and Regional Banks as we entered this week.

Biotechnology companies saw a positive trend from 2020 to 2021, which helped the Biotech index perform well. However, since 2022, rising interest rates have led to cash flow problems for many of these companies. On the bright side, developments in AI and machine learning are expected to speed up drug discovery and improve operations in the biotech and pharmaceutical industries, creating new growth opportunities.